重型肝炎恢复期干扰素联合软肝缩脾丸抗肝纤维化的研究

The anti-fibrosis effects of interferon and Ruangansuopiwan in treating severe hepatitis recovery patients

目的通过干扰素联合软肝缩脾丸治疗重型肝炎恢复期患者,探索阻断肝衰竭坏死后肝硬化发生的有效方法。方法39例恢复期重型肝炎病人,经过干扰素联合软肝缩脾丸1年治疗,观察肝功能、病毒学指标、肝纤四项及肝穿病理组织学变化。对照组38例同类病人,仅予一般的护肝治疗。结果治疗组经1月治疗,肝功能大部分复常;6月,HBV-DNA阴转或处于低水平,肝纤四项大部分复常;12月,部分病人HBeAg转阴,肝穿活检组织学改善。同期的对照组病人仍反复肝功能异常,肝纤维化指标大部分无改善。结论重型肝炎的恢复和重建是一个漫长而复杂的过程,干扰素联合软肝缩脾丸治疗对阻断肝衰竭坏死后肝硬化的发生具有明显效果。

Objective To investigate anti-fibrosis ways with interferon and Ruangansuopiwan after severe hepatitis. Methods Thirty-nine patients with the clinical presentation of acute liver failure（ALF） were treated with interferon and Ruangansuopiwan during a 12 months period. Liver biopsy was performed using the Menghini methods. Clinical data, viral loading and histological findings were evaluated in both treat group and control group. Results Histological activity and viral loading were improved greatly in treat group compared to control group. There was a strict statistical correlation between the poor prognosis and the necrosis found at routine histological examination. Conclusion Patients without clinical symptom of severe hepatitis have a long time to recover. Interferon and Ruangansuopiwan have great anti-fibrosis effect in patients after severe hepatitis.